Article ; Online: Real-world outcomes associated with afatinib use in patients with solid tumors harboring NRG1 gene fusions.
Lung cancer (Amsterdam, Netherlands)
2024 Volume 188, Page(s) 107469
Abstract: Objectives: Neuregulin-1 (NRG1) fusions may drive oncogenesis via constitutive activation of ErbB signaling. Hence, NRG1 fusion-driven tumors may be susceptible to ErbB-targeted therapy. Afatinib (irreversible pan-ErbB inhibitor) has demonstrated ... ...
| Abstract | Objectives: Neuregulin-1 (NRG1) fusions may drive oncogenesis via constitutive activation of ErbB signaling. Hence, NRG1 fusion-driven tumors may be susceptible to ErbB-targeted therapy. Afatinib (irreversible pan-ErbB inhibitor) has demonstrated activity in individual patients with NRG1 fusion-positive solid tumors. This study collected real-world data on demographics, clinical characteristics, and clinical outcomes in this patient population. Materials and methods: In this retrospective, multicenter, non-comparative cohort study, physicians in the US-based Cardinal Health Oncology Provider Extended Network collected data from medical records of patients with NRG1 fusion-positive solid tumors who received afatinib (afatinib cohort) or other systemic therapies (non-afatinib cohort) in any therapy line. Objectives included demographics, clinical characteristics, and outcomes (overall response rate [ORR], progression-free survival [PFS], and overall survival [OS]). Results: Patients (N = 110) with a variety of solid tumor types were included; 72 received afatinib, 38 other therapies. In the afatinib cohort, 70.8 % of patients received afatinib as second-line treatment and Eastern Cooperative Oncology Group performance status (ECOG PS) was 2-4 in 69.4 % at baseline. In the non-afatinib cohort, 94.7 % of patients received systemic therapy as first-line treatment and ECOG PS was 2-4 in 31.6 % at baseline. In the afatinib cohort, ORR was 37.5 % overall (43.8 % when received as first-line therapy); median PFS and OS were 5.5 and 7.2 months, respectively. In the non-afatinib cohort, ORR was 76.3 %; median PFS and OS were 12.9 and 22.6 months, respectively. Conclusion: This study provides real-world data on the characteristics of patients with NRG1 fusion-positive solid tumors treated with afatinib or other therapies; durable responses were observed in both groups. However, there were imbalances between the cohorts, and the study was not designed to compare outcomes. Further prospective/retrospective trials are required. |
||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| MeSH term(s) | Humans ; Afatinib/therapeutic use ; Afatinib/pharmacology ; Lung Neoplasms/drug therapy ; Retrospective Studies ; Cohort Studies ; Gene Fusion ; Mutation ; Protein Kinase Inhibitors/therapeutic use ; Neuregulin-1/genetics | ||||||||||
| Chemical Substances | Afatinib (41UD74L59M) ; Protein Kinase Inhibitors ; NRG1 protein, human ; Neuregulin-1 | ||||||||||
| Language | English | ||||||||||
| Publishing date | 2024-01-05 | ||||||||||
| Publishing country | Ireland | ||||||||||
| Document type | Multicenter Study ; Journal Article ; Research Support, Non-U.S. Gov't | ||||||||||
| ZDB-ID | 632771-0 | ||||||||||
| ISSN | 1872-8332 ; 0169-5002 | ||||||||||
| ISSN (online) | 1872-8332 | ||||||||||
| ISSN | 0169-5002 | ||||||||||
| DOI | 10.1016/j.lungcan.2024.107469 | ||||||||||
| Shelf mark |
|
||||||||||
| Database | MEDical Literature Analysis and Retrieval System OnLINE |
Full text online
More links
Kategorien
In stock of ZB MED Cologne/Königswinter
| Zs.A 2135: Show issues | Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (1.OG) ab Jg. 2022: Lesesaal (EG) |
|||
| Zs.MO 423: Show issues |
Order via subito
This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.